Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Centre Hospitalier Universitaire Vaudois
Massachusetts General Hospital
Jules Bordet Institute
National Cancer Institute (NCI)